Sanren Decoction Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Protecting Mitochondrial Function
Authors:
- 27 October 2025
- journal article
- research article
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 32 (3) , 223-231
Abstract
Objective To evaluate the effects of Sanren Decoction (SRD) on metabolic dysfunction-associated steatotic liver disease (MASLD) induced by high-fat diet (HFD) based on the protective effect of hepatocyte mitochondrial function. Methods Thirty-six male C57BL/6 mice were randomly assigned to 4 groups using stratified sampling based on body weight, including control, HFD, low-dose (10.09 g/kg) and high-dose (20.18 g/kg) SRD groups (n=9). MASLD model was induced in mice via a 16-week HFD. Liver histopathology was assessed using haematoxylin and eosin (HE) and Oil red O staining, while hepatic triglycerides (TG), serum alanine aminotransferase (ALT), fasting blood glucose (FBG), and fasting serum insulin levels were measured using commercial kits. Hepaticmetabolic profiling were analyzed and differential metabolite analysis was performed using partial least squares discriminant analysis and Kyoto Encyclopedia of Genes and Genomes pathways. Mitochondrial microstructure was assessed by electron microscopy. The protein expressions of respiratory chain complexes I–V were determined by Western blot analysis, while the activities of complexes I and II were measured using commercial kits. Results In the HFD-induced MASLD model, 4-week SRD treatment improved hepatic steatosis, inflammation, and hepatocyte ballooning (PPPPPP<0.05). Conclusion SRD exhibited hepatoprotective effects in MASLD, improving liver morphology, metabolism, and mitochondrial function, suggesting its potential as a therapeutic strategy for MASLD.Keywords
This publication has 31 references indexed in Scilit:
- Mitochondrial dysfunction in drug-induced hepatic steatosis: Recent findings and current conceptClinics and Research in Hepatology and Gastroenterology, 2025
- Resmetirom: First ApprovalDrugs, 2024
- Succinate as a signaling molecule in the mediation of liver diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023
- Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLDHepatology, 2022
- Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinomaActa Pharmaceutica Sinica B, 2021
- The assembly of succinate dehydrogenase: a key enzyme in bioenergeticsCellular and Molecular Life Sciences, 2019
- Citric Acid Cycle and Role of its Intermediates in MetabolismCell Biochemistry and Biophysics, 2013
- 2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of DeathJournal of Medical Toxicology, 2011
- Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese personsClinical Biochemistry, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005